Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com
EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer
April 3rd 2018The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Read More
Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months
April 2nd 2018In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.
Read More
Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer
March 28th 2018Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).
Read More
European Panel Backs New Nivolumab Dosing Schedules
March 26th 2018The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).
Read More
Venetoclax/Rituximab Positive PFS Data Published in NEJM
March 22nd 2018The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Read More
NCCN Recommends TTFields With Temozolomide for Newly Diagnosed GBM
March 21st 2018The NCCN has added the combination of TTFields (Optune) and temozolomide (Temodar) to its guidelines for Category 1 treatment of newly diagnosed glioblastoma following maximal safe resection and completion of radiation therapy.
Read More
Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer
March 7th 2018Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.
Read More